News

ivWatch Partners with National Infusion Center Association (NICA)

ivWatch, LLC, the IV safety company, today announced that it has partnered with the National Infusion Center Association (NICA), an independent, nonprofit trade association and accrediting body dedicated to representing ambulatory outpatient care settings where provider-administered biologics and specialty medications are prepared and administered.

In alignment, ivWatch and NICA are partnering with an emphasis on providing innovative and accessible solutions to freestanding infusion centers and their patients. The proprietary patient monitoring technology from ivWatch allows patients to have continuous IV site monitoring during infusions in the comfort and convenience of an outpatient setting.

“NICA has been the nation’s voice for independent infusion centers for more than a decade, overcoming countless barriers to care and access obstacles on behalf of patients and dedicated to ensuring that the nation’s infusion centers remain a safe, efficient, and cost-effective means of receiving consistent, high-quality care,” notes Brian Nyquist, MPH, NICA President and CEO. “We are excited to have ivWatch on board in 2024 as our trusted partner in helping our industry remain on the cutting edge of patient safety innovation.”

“Infusion centers are on the frontlines of IV patient safety, so this partnership is a natural fit,” says Erin Wendell, chief marketing officer at ivWatch. “It is also a perfect opportunity to work with this fast-growing segment of the healthcare industry in advocating for the increased adoption that a monitoring technology can play in reducing the severity of IV injuries while also mitigating the liability risks associated with IV extravasation and infiltration.”

This partnership comes at a monumental time of global adoption for ivWatch, as the company expands its reach to patients in all care areas that provide essential infusions. The company recently filed for 510(k) clearance for iron-based infusions to better protect patients not only from IV injuries but also the specific lifelong effects of irreversible skin staining that occurs with iron extravasations.

NICA and ivWatch will collaborate on several educational webinars relevant to infusion centers, including the recognition and interventions of early stages of IV extravasations to help promote safer delivery of IV therapy. The company will also exhibit at NICA’s annual conference on June 21-22, 2024, at the MGM Grand in Las Vegas in Booth 207. ivWatch will be a key participant at the exclusive NICA Infusion Center of Excellence (NICE) Experience, which provides an insider look at the ideal infusion center model. Products and technologies that improve patient care and promote patient safety will be displayed prominently. The event will provide a firsthand immersive experience for clinicians, administrators, managers, and owners.

 

Learn more here.

Recent News

05/18/2026

Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced the completion of its acquisition of Soleno Therapeutics, Inc., strengthening the company’s leadership in endocrinology and rare disease. The acquisition adds VYKAT™ XR (diazoxide choline) tablets, the first and only approved medicine for hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome, to

05/15/2026

OsteoStrong Expands in Virginia with New Location in Tysons, Virginia

OsteoStrong, a global leader in skeletal strength conditioning, is expanding in Northern Virginia with a new location in Tysons, Virginia, offering residents a cutting-edge, drug-free solution to improve bone density, strength and overall skeletal health in just 10-minute sessions per week. Located at 8609 Westwood Center Drive, Suite 625, Vienna, VA 22182, OsteoStrong Tysons VA

05/15/2026

ATCC Wins Prestigious National Institutes of Health Replication Prize for Advancing Reproducibility in Virus Research

ATCC is a winner of the National Institutes of Health (NIH) Common Fund Replication Prize, a prestigious national competition designed to advance scientific research by identifying strategies to make biomedical research more replicable. ATCC is recognized as one of 35 winners, and one of 15 selected winners for the Replication Exemplars Track. ATCC was recognized